Association of age at diagnosis and genetic mutations in patients with neuroblastoma

JAMA

Volumn 307, Issue 10, 2012, Pages 1062-1071

  Cheung, Nai Kong V ^a   Zhang, Jinghui ^b   Lu, Charles ^c   Parker, Matthew ^b   Bahrami, Armita ^b   Tickoo, Satish K ^a   Heguy, Adriana ^a   Pappo, Alberto S ^b   Federico, Sara ^b   Dalton, James ^b   Cheung, Irene Y ^a   Ding, Li ^c   Fulton, Robert ^c   Wang, Jianmin ^b   Chen, Xiang ^b   Becksfort, Jared ^b   Wu, Jianrong ^b   Billups, Catherine A ^b   Ellison, David ^b   Mardis, Elaine R ^c,d   Wilson, Richard K ^d   Downing, James R ^b   Dyer, Michael A ^b,e,f   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN ATRX; UNCLASSIFIED DRUG; ATRX PROTEIN, HUMAN; HELICASE; NUCLEAR PROTEIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE; ARTICLE; ATRX GENE; CANCER STAGING; CHILD; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METASTASIS; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROBLASTOMA; NONSENSE MUTATION; ONCOGENE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SOMATIC MUTATION; TELOMERE; VALIDATION PROCESS; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; MUTATION; NEWBORN; NUCLEOTIDE SEQUENCE; ONSET AGE; PATHOLOGY; TELOMERE HOMEOSTASIS;

ADOLESCENT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA HELICASES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; MUTATION; NEOPLASM METASTASIS; NEUROBLASTOMA; NUCLEAR PROTEINS; SEQUENCE ANALYSIS, DNA; TELOMERE HOMEOSTASIS; YOUNG ADULT;

EID: 84858248558     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.228     Document Type: Article

References (31)

1. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol. 1991;9(9):1599-1608.
2. Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group "Survey" 1982-1992. Eur J Cancer. 2000; 36(7):901-908. (Pubitemid 30214141)
3. Ladenstein R, Lasset C, Hartmann O, et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1993;11 (12):2330-2341. (Pubitemid 23353962)
4. Kushner BH, Kramer K, Cheung NK. Chronic neuroblastoma. Cancer. 2002;95(6):1366-1375.
5. Moroz V, Machin D, Faldum A, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011; 47(4):561-571.
6. Cohn SL, Pearson AD, London WB, et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-297.
7. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997; 79(10):2028-2035. (Pubitemid 27200389)
8. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol. 2003;41(6):508-515. (Pubitemid 37386067)
9. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: the Italian experience. Cancer. 2006;106(6):1409-1417. (Pubitemid 43363922)
10. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.
11. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329-334.
12. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
13. Wang J, Mullighan CG, Easton J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8(8):652-654.
14. Anderson J, Gibson S, Williamson D, et al. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatr Blood Cancer. 2006;46(7):820-824. (Pubitemid 43726433)
15. Castle JC, Biery M, Bouzek H, et al. DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing. BMC Genomics. 2010;11:244.
16. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
17. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques. 2008;44(6):807-809. (Pubitemid 351839149)
18. Hampton T. Studies probe role of telomere length in predicting, modulating cancer risk. JAMA. 2011; 305(22):2278-2279.
19. Pickett H, Reddel R. Alternative lengthening of telomeres in human cancer. In: Hiyama K, ed. Telomeres and Telomerase in Cancer. New York, NY: Humana; 2009.
20. Gibbons R. Alpha thalassaemia-mental retardation, X linked. Orphanet J Rare Dis. 2006;1:15.
21. Drané P, Ouararhni K, Depaux A, Shuaib M, Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010;24(12):1253-1265.
22. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140(5):678-691.
23. Law MJ, Lower KM, Voon HP, et al. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell. 2010;143(3):367-378.
24. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication- independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A. 2010;107(32):14075-14080.
25. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331(6021):1199-1203.
26. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr. 1991;119(5):725-732.
27. Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse: a retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45(16): 2835-2842.
28. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111-1116. (Pubitemid 16216827)
29. Deyell RJ, Attiyeh EF. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet. 2011; 204(3):113-121.
30. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16(11):2985-2995. (Pubitemid 27234938)
31. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286-3292.